
Takashi Matsushita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3169712/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern. Annals of the Rheumatic Diseases, 2022, 81, 742-744.	0.5	7
2	The compound LG283 inhibits bleomycin-induced skin fibrosis via antagonizing TGF-β signaling. Arthritis Research and Therapy, 2022, 24, 94.	1.6	6
3	Case of pembrolizumabâ€induced dermatomyositis with <scp>antiâ€</scp> transcription intermediary factor 1â€Î³ antibody. Journal of Dermatology, 2022, 49, .	0.6	3
4	A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor. Immunological Medicine, 2021, 44, 53-55.	1.4	6
5	Discrepancy in responses to dabrafenib plus trametinib combination therapy in intracranial and extracranial metastases in melanoma patients. Journal of Dermatology, 2021, 48, e82-e83.	0.6	1
6	Regulatory B cells and T cell Regulation in Cancer. Journal of Molecular Biology, 2021, 433, 166685.	2.0	43
7	Longâ€ŧerm changes in nail fold capillary abnormalities and serum fibroblast growth factor 23 levels in dermatomyositis patients with antiâ€melanoma differentiating antigen 5 antibody. Journal of Dermatology, 2021, 48, 106-109.	0.6	7
8	Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells. Scientific Reports, 2021, 11, 2106.	1.6	15
9	Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma. Journal of Dermatological Science, 2021, 101, 174-184.	1.0	22
10	Augmented interferon I signaling in a patient with COVID toes. Journal of Dermatology, 2021, 48, e242-e243.	0.6	0
11	SIRT1 decelerates morphological processing of oligodendrocyte cell lines and regulates the expression of cytoskeleton-related oligodendrocyte proteins. Biochemical and Biophysical Research Communications, 2021, 546, 7-14.	1.0	8
12	Sporadic Amyotrophic Lateral Sclerosis Due to a FUS P525L Mutation with Asymmetric Muscle Weakness and Anti-ganglioside Antibodies. Internal Medicine, 2021, 60, 1949-1953.	0.3	3
13	B Cell Role in the Pathogenesis of Systemic Sclerosis. Nishinihon Journal of Dermatology, 2021, 83, 397-401.	0.0	0
14	A case of antiâ€OJ antibodyâ€positive polymyositis with marked muscle involvement and interstitial lung disease. Journal of Cutaneous Immunology and Allergy, 2021, 4, 13-16.	0.2	0
15	A role for FcÎ ³ RIIB in the development of murine bleomycin-induced fibrosis. Journal of Dermatological Science, 2021, 104, 201-209.	1.0	2
16	Antiâ€transcriptional intermediary factor 1â€Î³ antibody as a biomarker in patients with dermatomyositis. Journal of Dermatology, 2020, 47, 64-68.	0.6	20
17	Availability of EuroQol-5-Dimensions-5-Level (EQ-5D-5L) as health-related QOL assessment for Japanese systemic sclerosis patients. Modern Rheumatology, 2020, 30, 681-686.	0.9	5
18	Human leukocyte antigen in Japanese patients with idiopathic inflammatory myopathy. Modern Rheumatology, 2020, 30, 696-702.	0.9	6

ΤΑΚΑSHI ΜΑΤSUSHITA

#	Article	IF	CITATIONS
19	CD22 and CD72 contribute to the development of scleroderma in a murine model. Journal of Dermatological Science, 2020, 97, 66-76.	1.0	8
20	Severe Mononeuritis Multiplex due to Rheumatoid Vasculitis in Rheumatoid Arthritis in Sustained Clinical Remission for Decades. Internal Medicine, 2020, 59, 705-710.	0.3	4
21	Adiposeâ€derived stromal/stem cells successfully attenuate the fibrosis of scleroderma mouse models. International Journal of Rheumatic Diseases, 2020, 23, 216-225.	0.9	25
22	Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study. Journal of Dermatology, 2020, 47, 1391-1394.	0.6	3
23	Association of functional (GA)n microsatellite polymorphism in the FLI1 gene with susceptibility to human systemic sclerosis. Rheumatology, 2020, 59, 3553-3562.	0.9	5
24	Clinical features of Japanese systemic sclerosis (SSc) patients negative for SScâ€related autoantibodies: A singleâ€center retrospective study. International Journal of Rheumatic Diseases, 2020, 23, 1219-1225.	0.9	4
25	A case of anti-NXP2 antibody-positive dermatomyositis with improvement of clinical symptoms and disappearance of autoantibody after resection of uterine cancer. European Journal of Dermatology, 2020, 30, 612-613.	0.3	0
26	A case of anti-NXP2 antibody-positive dermatomyositis with improvement of clinical symptoms and disappearance of autoantibody after resection of uterine cancer. European Journal of Dermatology, 2020, 30, 612-613.	0.3	1
27	A case of lymphoma-associated haemophagocytic syndrome in advanced-stage mycosis fungoides. European Journal of Dermatology, 2020, 30, 606-608.	0.3	0
28	Human case of subcutaneous nodule because of a novel genetic variation of Dirofilaria sp Journal of Dermatology, 2019, 46, 914-916.	0.6	1
29	Stevens–Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor. Journal of Dermatology, 2019, 46, e434-e436.	0.6	8
30	CD22 and CD72 cooperatively contribute to the development of the reverse Arthus reaction model. Journal of Dermatological Science, 2019, 95, 36-43.	1.0	3
31	Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population. Scientific Reports, 2019, 9, 16366.	1.6	15
32	Transplantation of Mesenchymal Stem Cells Improves Amyloid-β Pathology by Modifying Microglial Function and Suppressing Oxidative Stress. Journal of Alzheimer's Disease, 2019, 72, 867-884.	1.2	29
33	Elevated serum Bâ€cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease. Journal of Dermatology, 2019, 46, 1190-1196.	0.6	17
34	Early administration of galantamine from preplaque phase suppresses oxidative stress and improves cognitive behavior in APPswe/PS1dE9 mouse model of Alzheimer's disease. Free Radical Biology and Medicine, 2019, 145, 20-32.	1.3	31
35	Soluble CD163 is a potential biomarker in systemic sclerosis. Expert Review of Molecular Diagnostics, 2019, 19, 197-199.	1.5	12
36	Attenuation of murine sclerodermatous models by the selective S1P1 receptor modulator cenerimod. Scientific Reports, 2019, 9, 658.	1.6	13

3

#	Article	IF	CITATIONS
37	A case of dermatomyositis with the antiâ€signal recognition particle antibody that was successfully treated with prednisolone and intravenous immunoglobulin therapy. Journal of Dermatology, 2019, 46, e251-e253.	0.6	Ο
38	Evaluation of Mitochondrial Oxidative Stress in the Brain of a Transgenic Mouse Model of Alzheimer's Disease by in vitro Electron Paramagnetic Resonance Spectroscopy. Journal of Alzheimer's Disease, 2019, 67, 1079-1087.	1.2	8
39	Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the <scp>CX</scp> ₃ <scp>CL</scp> 1/ <scp>CX</scp> 3 <scp>CR</scp> 1 Pathway in Experimental Mouse Models of Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1923-1934.	2.9	11
40	Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8+ T Cells. Journal of Investigative Dermatology, 2019, 139, 1535-1544.e1.	0.3	26
41	CD14 and Toll-Like Receptor 4 Promote Fibrillar Aβ42 Uptake by Microglia Through A Clathrin-Mediated Pathway. Journal of Alzheimer's Disease, 2019, 68, 323-337.	1.2	20
42	A case of juvenile localized scleroderma with anti-topoisomerase I antibody. European Journal of Dermatology, 2019, 29, 443-444.	0.3	1
43	Regulatory and effector B cells: Friends or foes?. Journal of Dermatological Science, 2019, 93, 2-7.	1.0	84
44	Long-term follow-up of finger passive range of motion in Japanese systemic sclerosis patients treated with self-administered stretching. Modern Rheumatology, 2019, 29, 484-490.	0.9	5
45	Successful radiation therapy for primary cutaneous follicle center lymphoma. Journal of Case Reports in Medicine, 2019, 8, .	0.0	0
46	Increased expression levels of Fcl ³ RIIB on naÃ ⁻ ve and double-negative memory B cells in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 23-31.	0.4	0
47	Blockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis. Arthritis Research and Therapy, 2018, 20, 46.	1.6	21
48	Foodâ€dependent exerciseâ€induced anaphylaxis due to shrimp associated with 43ÂkDa, a new antigen. Journal of Dermatology, 2018, 45, 366-367.	0.6	5
49	Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. Journal of Thoracic Disease, 2018, 10, 799-807.	0.6	19
50	Increased interleukinâ€9 levels in sera, muscle and skin of patients with dermatomyositis. Journal of Dermatology, 2018, 45, 1023-1025.	0.6	4
51	BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Science Advances, 2018, 4, eaas9944.	4.7	98
52	A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. European Journal of Dermatology, 2017, 27, 193-194.	0.3	12
53	Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease. American Journal of Pathology, 2017, 187, 841-850.	1.9	18
54	Dual aspects of B cells in tumor immunity; B cells are capable of positive and negative regulation for tumor immunity against B16 melanoma. Journal of Dermatological Science, 2017, 86, e63.	1.0	0

ΤΑΚΑSHI MATSUSHITA

#	Article	IF	CITATIONS
55	An update on biomarker discovery and use in systemic sclerosis. Expert Review of Molecular Diagnostics, 2017, 17, 823-833.	1.5	17
56	A unique CD9 + CD80 + regulatory B cell inhibits contact hypersensitivity response. Journal of Dermatological Science, 2017, 86, e2.	1.0	0
57	Classification of Japanese patients with mild/early systemic sclerosis (SSc) by the 2013 ACR/EULAR classification criteria for SSc. Modern Rheumatology, 2017, 27, 614-617.	0.9	5
58	Case of antiâ€transcriptional intermediary factorâ€1â€positive dermatomyositis associated with breast cancer developing over 10 years. Journal of Dermatology, 2017, 44, 972-973.	0.6	5
59	Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. Journal of Autoimmunity, 2017, 76, 101-107.	3.0	4
60	Antimelanoma differentiationâ€associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. British Journal of Dermatology, 2017, 176, 395-402.	1.4	131
61	Watermelon stomach and colon in a patient with diffuse cutaneous systemic sclerosis. Modern Rheumatology, 2017, 27, 376-377.	0.9	0
62	Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice. Journal of Alzheimer's Disease, 2016, 55, 1235-1247.	1.2	25
63	Severe pneumonitis after nivolumab treatment in a patient with melanoma. Allergology International, 2016, 65, 487-489.	1.4	25
64	A crucial role of L-selectin in C protein-induced experimental polymyositis of mice. Journal of Dermatological Science, 2016, 84, e9.	1.0	0
65	The inhibitor of p38 MAP kinase suppresses skin fibrosis in the sclerodermatous chronic GVHD. Journal of Dermatological Science, 2016, 84, e15.	1.0	0
66	Decreased levels of regulatory B cells in patients with systemic sclerosis: Association with autoantibody production and disease activity. Journal of Dermatological Science, 2016, 84, e96.	1.0	0
67	A novel splenic B1 regulatory cell subset suppresses allergic disease through phosphatidylinositol 3-kinase–Akt pathway activation. Journal of Allergy and Clinical Immunology, 2016, 138, 1170-1182.e9.	1.5	54
68	The Role of B Cells in Systemic Sclerosis. , 2016, , 173-185.		0
69	Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology, 2016, 55, 263-267.	0.9	84
70	Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. PLoS ONE, 2016, 11, e0154255.	1,1	25
71	Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies. PLoS ONE, 2016, 11, e0154746.	1.1	78
72	A case of Merkel cell carcinoma of the right big toe with Merkel cell polyomavirus infection. Skin Cancer, 2016, 31, 30-34.	0.1	0

ΤΑΚΑSΗΙ ΜΑΤSUSHITA

#	Article	IF	CITATIONS
73	A case of myxofibrosarcoma with lung metastasis. Skin Cancer, 2016, 31, 35-39.	0.1	Ο
74	Primary Cutaneous NK/T-cell Lymphoma, Nasal Type and CD56-positive Peripheral T-cell Lymphoma. American Journal of Surgical Pathology, 2015, 39, 1-12.	2.1	73
75	Clinical and Immunologic Predictors of Scleroderma Renal Crisis in Japanese Systemic Sclerosis Patients With Anti–RNA Polymerase III Autoantibodies. Arthritis and Rheumatology, 2015, 67, 1045-1052.	2.9	70
76	High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies. Modern Rheumatology, 2015, 25, 798-801.	0.9	11
77	The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Modern Rheumatology, 2014, 24, 377-379.	0.9	5
78	A Crucial Role of Lâ€ s electin in C Protein–Induced Experimental Polymyositis in Mice. Arthritis and Rheumatology, 2014, 66, 1864-1871.	2.9	16
79	Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. Journal of Dermatological Science, 2014, 74, 214-221.	1.0	37
80	Long-term clinical and radiological improvement of chronic acquired hepatocerebral degeneration after obliteration of portosystemic shunt: Report of a case. Journal of the Neurological Sciences, 2014, 346, 303-306.	0.3	5
81	B Cells Promote Tumor Immunity against B16F10 Melanoma. American Journal of Pathology, 2014, 184, 3120-3129.	1.9	28
82	Regulatory B Cells in Mouse Models of Systemic Lupus Erythematosus (SLE). Methods in Molecular Biology, 2014, 1190, 195-205.	0.4	11
83	Altered expression of dermokine in skin disorders. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 867-875.	1.3	16
84	Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia, 2013, 27, 170-182.	3.3	145
85	Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis. Rheumatology, 2013, 52, 242-251.	0.9	21
86	The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Modern Rheumatology, 2013, , 1.	0.9	3
87	Dermokine inhibits ELR+CXC chemokine expression and delays early skin wound healing. Journal of Dermatological Science, 2013, 70, 34-41.	1.0	28
88	B-cell linker protein expression contributes to controlling allergic and autoimmune diseases by mediating IL-10 production in regulatory B cells. Journal of Allergy and Clinical Immunology, 2013, 131, 1674-1682.e9.	1.5	76
89	Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. Blood, 2013, 121, 3274-3283.	0.6	92
90	Scleroderma: recent lessons from murine models and implications for future therapeutics. Expert Review of Dermatology, 2013, 8, 527-539.	0.3	4

ΤΑΚΑSΗΙ ΜΑΤSUSHITA

#	Article	IF	CITATIONS
91	Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Modern Rheumatology, 2013, 23, 913-919.	0.9	3
92	FTY720 Ameliorates Murine Sclerodermatous Chronic Graftâ€Versusâ€Host Disease by Promoting Expansion of Splenic Regulatory Cells and Inhibiting Immune Cell Infiltration Into Skin. Arthritis and Rheumatism, 2013, 65, 1624-1635.	6.7	40
93	Anti-topoisomerase I antibody levels as serum markers of skin sclerosis in systemic sclerosis. Journal of Dermatology, 2013, 40, 89-93.	0.6	9
94	Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Annals of the Rheumatic Diseases, 2013, 72, 151-153.	0.5	77
95	Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome. PLoS ONE, 2013, 8, e60442.	1.1	306
96	Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Modern Rheumatology, 2013, 23, 913-919.	0.9	7
97	IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2012, 132, 2752-2761.	0.3	55
98	Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Annals of the Rheumatic Diseases, 2012, 71, 710-713.	0.5	220
99	High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Modern Rheumatology, 2012, 22, 892-898.	0.9	29
100	Two cases of livedo vasculopathy with non riteria antiphospholipid antibodies. Journal of Dermatology, 2012, 39, 1026-1030.	0.6	2
101	Potential roles of interleukinâ€17A in the development of skin fibrosis in mice. Arthritis and Rheumatism, 2012, 64, 3726-3735.	6.7	118
102	Host-Derived MCP-1 and MIP-1α Regulate Protective Anti-Tumor Immunity to Localized and Metastatic B16 Melanoma. American Journal of Pathology, 2012, 180, 365-374.	1.9	47
103	Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature, 2012, 491, 264-268.	13.7	568
104	Basophils and mast cells play critical roles for leukocyte recruitment in IgE-mediated cutaneous reverse passive Arthus reaction. Journal of Dermatological Science, 2012, 67, 181-189.	1.0	10
105	Sequentially appearing erythema nodosum, erythema multiforme and Henoch-Schönlein purpura in a patient with Mycoplasma pneumoniae infection: a case report. Journal of Medical Case Reports, 2012, 6, 398.	0.4	14
106	Skin sclerosis as a manifestation of POEMS syndrome. Journal of Dermatology, 2012, 39, 922-926.	0.6	7
107	Myositisâ€specific antiâ€155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis and Rheumatism, 2012, 64, 513-522.	6.7	245
108	High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Modern Rheumatology, 2012, 22, 892-898.	0.9	16

ΤΑΚΑSHI ΜΑΤSUSHITA

#	Article	IF	CITATIONS
109	Amplified B Lymphocyte CD40 Signaling Drives Regulatory B10 Cell Expansion in Mice. PLoS ONE, 2011, 6, e22464.	1.1	62
110	Inducible Costimulator (ICOS) and ICOS Ligand Signaling Has Pivotal Roles in Skin Wound Healing via Cytokine Production. American Journal of Pathology, 2011, 179, 2360-2369.	1.9	36
111	Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neuroscience Letters, 2011, 502, 41-45.	1.0	83
112	Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood, 2011, 117, 530-541.	0.6	969
113	Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clinical Rheumatology, 2011, 30, 231-237.	1.0	78
114	Use of Serum Clara Cell 16-kDa (CC16) Levels as a Potential Indicator of Active Pulmonary Fibrosis in Systemic Sclerosis. Journal of Rheumatology, 2011, 38, 877-884.	1.0	47
115	Association between nail-fold capillary findings and disease activity in dermatomyositis. Rheumatology, 2011, 50, 1091-1098.	0.9	63
116	Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatology, 2011, 147, 391.	1.7	293
117	Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. Journal of Clinical Investigation, 2011, 121, 4268-4280.	3.9	156
118	B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Annals of the New York Academy of Sciences, 2010, 1183, 38-57.	1.8	394
119	Regulatory B Cells (B10 Cells) and Regulatory T Cells Have Independent Roles in Controlling Experimental Autoimmune Encephalomyelitis Initiation and Late-Phase Immunopathogenesis. Journal of Immunology, 2010, 185, 2240-2252.	0.4	341
120	Protective and Pathogenic Roles for B Cells during Systemic Autoimmunity in NZB/W F1 Mice. Journal of Immunology, 2010, 184, 4789-4800.	0.4	136
121	Identifying Regulatory B Cells (B10 Cells) that Produce IL-10 in Mice. Methods in Molecular Biology, 2010, 677, 99-111.	0.4	106
122	Regulatory B cells that produce IL-10: AÂbreath of fresh air in allergic airway disease. Journal of Allergy and Clinical Immunology, 2010, 125, 1125-1127.	1.5	27
123	Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis. Journal of the American Academy of Dermatology, 2010, 62, 142-144.	0.6	5
124	The Development and Function of Regulatory B Cells Expressing IL-10 (B10 Cells) Requires Antigen Receptor Diversity and TLR Signals. Journal of Immunology, 2009, 182, 7459-7472.	0.4	443
125	Clinical association of serum CD137 (4-1BB) levels in patients with systemic sclerosis. Journal of Dermatological Science, 2009, 53, 159-161.	1.0	3
126	Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension. Journal of Dermatological Science, 2009, 55, 66-67.	1.0	8

ΤΑΚΑSHI MATSUSHITA

#	Article	IF	CITATIONS
127	B-lymphocyte depletion for the treatment of multiple sclerosis: now things really get interesting. Expert Review of Neurotherapeutics, 2009, 9, 309-312.	1.4	6
128	Establishment of Experimental Eosinophilic Vasculitis by IgE-Mediated Cutaneous Reverse Passive Arthus Reaction. American Journal of Pathology, 2009, 174, 2225-2233.	1.9	15
129	Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clinical and Experimental Immunology, 2009, 159, 176-184.	1.1	28
130	Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis. Experimental Dermatology, 2008, 17, 197-202.	1.4	21
131	B″ymphocyte contributions to human autoimmune disease. Immunological Reviews, 2008, 223, 284-299.	2.8	306
132	The Loss of MCP-1 Attenuates Cutaneous Ischemia–Reperfusion Injury in a Mouse Model of Pressure Ulcer. Journal of Investigative Dermatology, 2008, 128, 1838-1851.	0.3	64
133	The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. British Journal of Dermatology, 2008, 158, 487-495.	1.4	108
134	Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?. Journal of Dermatological Science, 2008, 50, 240-242.	1.0	110
135	Elevated Serum Insulin-like Growth Factor (IGF-1) and IGF Binding Protein-3 Levels in Patients with Systemic Sclerosis: Possible Role in Development of Fibrosis. Journal of Rheumatology, 2008, 35, 2363-2371.	1.0	60
136	A Case of Acute Cutaneous Graft-versus-Host Disease Mimicking Psoriasis Vulgaris. Dermatology, 2008, 216, 64-67.	0.9	26
137	Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Annals of the Rheumatic Diseases, 2008, 67, 867-872.	0.5	50
138	Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. Journal of Clinical Investigation, 2008, 118, 3420-30.	3.9	762
139	Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology, 2007, 46, 25-28.	0.9	277
140	Endothelial selectins regulate skin wound healing in cooperation with L-selectin and ICAM-1. Journal of Leukocyte Biology, 2007, 82, 519-531.	1.5	39
141	Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 cooperatively contribute to the cutaneous Arthus reaction. Journal of Leukocyte Biology, 2007, 81, 1197-1204.	1.5	16
142	Intercellular Adhesion Molecule-1 Deficiency Attenuates the Development of Skin Fibrosis in Tight-Skin Mice. Journal of Immunology, 2007, 179, 698-707.	0.4	35
143	Phase-Dependent Roles of E-Selectin during Chronic Contact Hypersensitivity Responses. American Journal of Pathology, 2007, 170, 1649-1658.	1.9	12
144	BAFF Antagonist Attenuates the Development of Skin Fibrosis in Tight-Skin Mice. Journal of Investigative Dermatology, 2007, 127, 2772-2780.	0.3	69

TAKASHI MATSUSHITA

#	Article	IF	CITATIONS
145	Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Experimental Dermatology, 2007, 16, 87-93.	1.4	53
146	Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies. Rheumatology International, 2007, 28, 113-119.	1.5	4
147	Increased serum soluble CD40 levels in patients with systemic sclerosis. Journal of Rheumatology, 2007, 34, 353-8.	1.0	20
148	Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. Journal of Rheumatology, 2007, 34, 1012-8.	1.0	62
149	Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. Journal of Rheumatology, 2007, 34, 2056-62.	1.0	50
150	Inhibitory Role of CD19 in the Progression of Experimental Autoimmune Encephalomyelitis by Regulating Cytokine Response. American Journal of Pathology, 2006, 168, 812-821.	1.9	109
151	E- and P-Selectins Synergistically Inhibit Bleomycin-Induced Pulmonary Fibrosis. American Journal of Pathology, 2006, 169, 740-749.	1.9	14
152	B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis. American Journal of Pathology, 2006, 169, 954-966.	1.9	195
153	Regulation of local and metastatic host-mediated anti-tumour mechanisms by l-selectin and intercellular adhesion molecule-1. Clinical and Experimental Immunology, 2006, 143, 216-227.	1.1	34
154	Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis and Rheumatism, 2006, 54, 192-201.	6.7	242
155	A Clue for Telangiectasis in Systemic Sclerosis: Elevated Serum Soluble Endoglin Levels in Patients with the Limited Cutaneous Form of the Disease. Dermatology, 2006, 213, 88-92.	0.9	38
156	L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury. Journal of Leukocyte Biology, 2006, 79, 696-705.	1.5	20
157	Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Annals of the Rheumatic Diseases, 2006, 65, 124-126.	0.5	37
158	Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. Journal of Rheumatology, 2006, 33, 275-84.	1.0	106
159	The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis. Journal of Rheumatology, 2006, 33, 1586-92.	1.0	43
160	Abnormal Natural Killer Cell Function in Systemic Sclerosis: Altered Cytokine Production and Defective Killing Activity. Journal of Investigative Dermatology, 2005, 125, 731-737.	0.3	55
161	Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology, 2005, 44, 873-878.	0.9	29
162	Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. Journal of Dermatological Science, 2005, 40, 215-217.	1.0	51

Τακαςμι Ματςυςμιτα

#	Article	IF	CITATIONS
163	Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. British Journal of Rheumatology, 2004, 43, 1261-1266.	2.5	73
164	Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clinical and Experimental Immunology, 2004, 138, 357-363.	1.1	76
165	Childhood Capillary Hemangioma Presenting as Infantile Perianal Protrusion. Dermatology, 2003, 207, 408-409.	0.9	5
166	Epstein-Barr virus-associated T-cell lymphoma: a case of eyelid swelling and intramuscular infiltration mimicking dermatomyositis. British Journal of Dermatology, 2002, 147, 1244-1248.	1.4	23
167	Comparison of cyclic compression, cyclic distraction and rigid fixation: Bone healing in rabbits. Acta Orthopaedica, 1998, 69, 95-98.	1.4	27
168	The diameter of callus in leg lengthening 28 tibial lengthenings in 14 patients with achondroplasia. Acta Orthopaedica, 1998, 69, 306-310.	1.4	7
169	Interlocking Intramedullary Nail Method for the Treatment of Femoral and Tibial Fractures in Cats and Small Dogs Journal of Veterinary Medical Science, 1998, 60, 119-122.	0.3	19
170	Influence of femoral lengthening on hip joint space in posttraumatic femoral shortening. Acta Orthopaedica, 1997, 68, 541-544.	1.4	1
171	Callus formation in femur and tibia during leg lengthening:7 patients examined with DXA. Acta Orthopaedica, 1996, 67, 158-160.	1.4	11
172	The Hand and Environment (4). Journal of UOEH, 1982, 4, 33-40.	0.3	0
173	Cytokineâ€producing Bâ€cell balance associates with skin fibrosis in patients with systemic sclerosis. Journal of Dermatology, 0,	0.6	3